NOVO.B.DK

259.65

+1.39%↑

GMAB.DK

1,807.5

+0.81%↑

HLUNB.DK

42.4

+1.83%↑

ZEAL.DK

327.2

+3.74%↑

AMBUB.DK

70.65

+4.05%↑

NOVO.B.DK

259.65

+1.39%↑

GMAB.DK

1,807.5

+0.81%↑

HLUNB.DK

42.4

+1.83%↑

ZEAL.DK

327.2

+3.74%↑

AMBUB.DK

70.65

+4.05%↑

NOVO.B.DK

259.65

+1.39%↑

GMAB.DK

1,807.5

+0.81%↑

HLUNB.DK

42.4

+1.83%↑

ZEAL.DK

327.2

+3.74%↑

AMBUB.DK

70.65

+4.05%↑

NOVO.B.DK

259.65

+1.39%↑

GMAB.DK

1,807.5

+0.81%↑

HLUNB.DK

42.4

+1.83%↑

ZEAL.DK

327.2

+3.74%↑

AMBUB.DK

70.65

+4.05%↑

NOVO.B.DK

259.65

+1.39%↑

GMAB.DK

1,807.5

+0.81%↑

HLUNB.DK

42.4

+1.83%↑

ZEAL.DK

327.2

+3.74%↑

AMBUB.DK

70.65

+4.05%↑

Search

Coloplast A-S (Class B)

Fermé

446.5 2.9

Résumé

Variation du prix de l'action

24h

Actuel

Min

440

Max

446.5

Chiffres clés

By Trading Economics

Revenu

522M

1.4B

Ventes

83M

7B

P/E

Moyenne du Secteur

24.148

63.808

BPA

6.32

Rendement du dividende

5.41

Marge bénéficiaire

19.835

Employés

16,983

EBITDA

309M

2.3B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+11.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

5.41%

2.38%

Prochains Résultats

12 mai 2026

Date du Prochain Dividende

20 mai 2026

Date du Prochain Détachement de Dividende

18 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-22B

96B

Ouverture précédente

443.6

Clôture précédente

446.5

Coloplast A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 avr. 2026, 20:26 UTC

Acquisitions, Fusions, Rachats

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 avr. 2026, 18:15 UTC

Principaux Événements d'Actualité

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 avr. 2026, 16:49 UTC

Principaux Événements d'Actualité

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 avr. 2026, 16:49 UTC

Principaux Événements d'Actualité

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 avr. 2026, 22:58 UTC

Résultats

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 avr. 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 avr. 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 avr. 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17 avr. 2026, 20:52 UTC

Résultats

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 avr. 2026, 20:50 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

17 avr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 avr. 2026, 20:29 UTC

Résultats

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 avr. 2026, 20:11 UTC

Acquisitions, Fusions, Rachats

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 avr. 2026, 19:34 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Global Equities Roundup: Market Talk

17 avr. 2026, 19:34 UTC

Market Talk
Résultats
Acquisitions, Fusions, Rachats

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 avr. 2026, 19:31 UTC

Market Talk
Principaux Événements d'Actualité

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 avr. 2026, 19:26 UTC

Market Talk

U.S. Natural Gas Futures Edge Up -- Market Talk

17 avr. 2026, 19:21 UTC

Market Talk

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 avr. 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 avr. 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 avr. 2026, 18:57 UTC

Principaux Événements d'Actualité

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 avr. 2026, 18:53 UTC

Acquisitions, Fusions, Rachats

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 avr. 2026, 18:53 UTC

Acquisitions, Fusions, Rachats

UCB 2026 Rev Guidance Unchanged

17 avr. 2026, 18:52 UTC

Acquisitions, Fusions, Rachats

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 avr. 2026, 18:52 UTC

Acquisitions, Fusions, Rachats

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 avr. 2026, 18:14 UTC

Market Talk
Principaux Événements d'Actualité

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 avr. 2026, 18:00 UTC

Principaux Événements d'Actualité

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 avr. 2026, 18:00 UTC

Principaux Événements d'Actualité

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 avr. 2026, 17:31 UTC

Market Talk
Principaux Événements d'Actualité

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 avr. 2026, 17:26 UTC

Market Talk
Résultats

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Comparaison

Variation de prix

Coloplast A-S (Class B) prévision

Objectif de Prix

By TipRanks

11.86% hausse

Prévisions sur 12 Mois

Moyen 901.38 DKK  11.86%

Haut 1,056 DKK

Bas 720 DKK

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

2

Achat

4

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat